Clinical Trial Update: Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing tocilizumab for Graves' ophthalmopathy (thyroid eye disease) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy
• Thyroid Eye Disease
• Thyroid-associated Ophthalmopathy

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hospital Clinico Universitario de Santiago | Conditions: Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy | Phase 3 | Status: COMPLETED